From Dog

Selegiline is a monamine-oxidase inhibitor used primarily for treatment of canine cognitive dysfunction syndrome (CDS) [1]. Therapeutic effects of selegiline are thought to result in part from enhanced catecholaminergic nerve function and increased dopamine levels in the CNS[2].

It has been trialed in the treatment of hyperadrenocorticism but appears ineffective at moderating adrenal function in this disease[3].

Available in 2, 5, 10, 15, and 30 mg tablets.

Recommended dose in dogs is 1 mg/kg (0.45 mg/lb), administered in the morning. During the first two months of therapy, the patient should be re-evaluated regularly for clinical response by history and physical examination.

The dose can be increased to a maximum of 2 mg/kg once daily after the initial one month trial, or discontinued if poor response is observed.


  1. Mills D & Ledger R (2001) The effects of oral selegiline hydrochloride on learning and training in the dog: a psychobiological interpretation. Prog Neuropsychopharmacol Biol Psychiatry 25(8):1597-1613
  2. Knoll J et al (1996) (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-) PPAP], act primarily as potent stimulants of action potential - transmitter release coupling in the catecholaminergic neurons. Life Sci 58:817-827
  3. Braddock JA et al (2004) Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism. Aust Vet J 82(5):272-277